Soleno Net Income Applicable To Common Shares from 2010 to 2026
| SLNO Stock | USD 41.53 1.95 4.93% |
Net Loss | First Reported 2012-12-31 | Previous Quarter -8.4 M | Current Value -8.5 M | Quarterly Volatility 4 M |
Check Soleno Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Soleno Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 197.5 K or Selling General Administrative of 127.8 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.85 or Days Sales Outstanding of 53.01. Soleno financial statements analysis is a perfect complement when working with Soleno Therapeutics Valuation or Volatility modules.
Soleno | Net Income Applicable To Common Shares | Build AI portfolio with Soleno Stock |
Evaluating Soleno Therapeutics's Net Income Applicable To Common Shares across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Soleno Therapeutics's fundamental strength.
Latest Soleno Therapeutics' Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of Soleno Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Soleno Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Soleno Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
Soleno Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | (19,583,973) | |
| Coefficient Of Variation | (31.26) | |
| Mean Deviation | 5,441,863 | |
| Median | (15,908,546) | |
| Standard Deviation | 6,121,069 | |
| Sample Variance | 37.5T | |
| Range | 17.6M | |
| R-Value | (0.72) | |
| Mean Square Error | 19.2T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | (873,271) | |
| Total Sum of Squares | 599.5T |
Soleno Net Income Applicable To Common Shares History
About Soleno Therapeutics Financial Statements
Soleno Therapeutics investors utilize fundamental indicators, such as Net Income Applicable To Common Shares, to predict how Soleno Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -21.7 M | -22.7 M |
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Soleno Stock
Moving against Soleno Stock
| 0.52 | ENGN | enGene Holdings Common | PairCorr |
| 0.5 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.47 | DSGN | Design Therapeutics | PairCorr |
| 0.34 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Soleno Therapeutics Correlation against competitors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Will Biotechnology sector continue expanding? Could Soleno diversify its offerings? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Soleno Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Soleno Therapeutics requires distinguishing between market price and book value, where the latter reflects Soleno's accounting equity. The concept of intrinsic value - what Soleno Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Soleno Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Soleno Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.